Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paxlovid for post-COVID syndrome
2022-003855-32Phase 2Completed
- Sponsor
- Karolinska Institutet
- Start
- Jan 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in post-COVID syndrome comparing Paxlovid arm with Placebo/ritonavir arm (2 arms). Primary endpoint: Change from baseline on EQ-5D functional scale at day 16. Started Jan 2023; status: completed.
02
Drugs
Nirmatrelvir
03
Conditions
post-COVID syndrome
Beyond the preview
Go deeper on 2022-003855-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-003855-32.